AACR Conference Coverage

AstraZeneca Showcases Next-generation Oncology Pipeline Addressing Unmet Patient Needs At AACR Annual Meeting

(AstraZeneca) Mar 14, 2019 - AstraZeneca will share pioneering research and development across its successful Oncology portfolio and extensive next-generation pipeline at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, USA, 29 March to 3 April 2019. The new research will showcase AstraZeneca’s potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, taking the DNA Damage Response (DDR) pipeline beyond PARP inhibition. Additional highlights include new insights from the MYSTIC and TATTON trials for Imfinzi (durvalumab) and Tagrisso (osimertinib) in predicting response and addressing treatment resistance in lung cancer. In total, data from 84 presentations will illustrate the progress of AstraZeneca’s Oncology pipeline, with 28 abstracts reporting new Immuno-Oncology (IO) data, 33 focused on complementary biological pathways exploring the DDR mechanism, and 20 on tumour drivers and resistance mechanisms.

read corporate press release

Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019

(Amgen) Feb 28, 2019 - First preclinical data to be presented on AMG 510, a first-in-class KRASG12C inhibitor for solid tumors. New preclinical data evaluating AMG 757 to highlight half-life extended Bite® immunotherapy. AMG 176 preclinical data showcase potential in combination with standard of care treatments for acute myeloid leukemia.

read corporate press release

Liquid Biopsy-based Test As Good As Tissue-based Test for Identifying Treatment for Lung Cancer

(AACR) Feb 27, 2019 - Guardant360, a liquid biopsy test that detects all guideline-recommended biomarkers in newly diagnosed metastatic non-small cell lung cancer (NSCLC), detected biomarkers at a rate similar to that of standard-of-care tissue genotyping tests but with a faster turn-around time, according to data presented during a media preview of the AACR Annual Meeting 2019, to be held March 29-April 3, in Atlanta. “About 30 percent of lung cancers can now be treated with molecularly targeted therapies and the response rates using these treatments are much higher than with chemotherapy,” said Vassiliki Papadimitrakopoulou, MD, professor of medicine in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. “But to identify patients who will benefit from these therapies, we need to ensure all patients are tested for these targetable mutations.”

read press release

Prostate Cancer Patients With Cardiovascular Disease Had Higher Mortality After Starting Abiraterone Acetate

(AACR) Feb 27, 2019 - Patients with advanced prostate cancer who had pre-existing cardiovascular disease had higher risk of mortality in the six months after starting abiraterone acetate (Zytiga) treatment compared with those who had no pre-existing cardiovascular disease, according to data presented during a media preview of the AACR Annual Meeting 2019, which will be held March 29–April 3, in Atlanta. “Patients with a history of significant cardiovascular disease or uncontrolled hypertension are almost always excluded from clinical trials of abiraterone acetate,” said Grace Lu-Yao, PhD, MPH, associate director for Population Science at the Sidney Kimmel Cancer Center at Jefferson in Philadelphia. “However, in the real-world setting, these conditions are very common among men with prostate cancer.

read press release

Dietary Factors Affecting Gut Microbiome May Influence Response to Immunotherapy in Melanoma Patients

(AACR) Feb 27, 2019 - Among melanoma patients treated with anti-PD-1 immunotherapy, consumption of a high-fiber diet was associated with higher gut microbiome diversity and better response to treatment, according to data presented during a media preview of the AACR Annual Meeting 2019, to be held March 29-April 3 in Atlanta. “We found that diet and supplements appear to have an effect on a patient’s ability to respond to cancer immunotherapy, most likely due to changes in their gut microbiome,” said Christine Spencer, PhD, research scientist at the Parker Institute for Cancer Immunotherapy. “The gut microbiome plays a big role in moderating the immune system, so the idea that we could potentially change the microbiome—whether by diet or other means—to improve response to immunotherapy treatment is really exciting.”

read press release

Survey of Young-onset Colorectal Cancer Patients Suggests Misdiagnosis May Be Common

(AACR) Feb 27, 2019 - Many patients diagnosed with colorectal cancer before age 50 were initially misdiagnosed, which may lead to diagnosis at an advanced stage of the disease, according to survey results presented during a media preview of the AACR Annual Meeting 2019, to be held March 29-April 3, in Atlanta. “Despite declining incidence in older adults, there has been a rapid and alarming rise in colorectal cancer incidence among young adults in recent decades,” said the study’s lead author, Ronit Yarden, PhD, MHSA, director of medical affairs at the Colorectal Cancer Alliance, a patient advocacy organization based in Washington, D.C. “We do not yet know the cause of the rising incidence in younger patients, and there is little awareness of this trend among health care providers.”

read press release

Guardant’s Blood Test Might Replace Biopsies For Some Lung Cancer Patients, Study Says

(STAT) Feb 27, 2019 - Could a blood test help more lung cancer patients get drugs that are targeted to the genetic weaknesses of their tumors? Yes, according to summary results of a 282-patient clinical trial being made available Wednesday. The result is a boon for Guardant Health, the San Francisco-based startup that sells the test, Guardant360, which is a “liquid biopsy” that works by detecting fragments of DNA in the bloodstream.

read article

New Study Suggests Diet May Affect Response To Cancer Immunotherapy Drugs

(Forbes) Feb 27, 2019 - People with a type of skin cancer who consumed a high-fiber diet responded better to immunotherapy treatment than those with poorer diets, according to data presented at a media preview of the AACR annual meeting. Melanoma is a type of skin cancer which although very treatable if caught early, still kills approximately 9,000 Americans a year, mainly people who are diagnosed a more advanced stage of disease where the cancer has spread to other parts of the body. Immunotherapy drugs such as those targeting PD-1/PD-L1 or CTLA-4 as well as T-VEC, the first ever viral therapy for cancer treatment to be FDA-approved, have had a remarkable impact on the survival from advanced melanoma.

read article

Colon Cancer Often Misdiagnosed, Treatment Delayed In Many Younger Patients

(NBCNews.com) Feb 27, 2019 - Some patients under 50 experience symptoms for up to a year before seeing a doctor prompting some experts to encourage earlier screening. Many younger patients with colon cancer are initially misdiagnosed, which often leads to their disease being discovered at an advanced stage. Researchers also found that for many younger patients, it took visits to multiple doctors before the correct diagnosis was made, according to survey results released Wednesday, to be presented next month at the annual meeting of the American Association for Cancer Research.

read article

TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

(Markets Insider) Feb 28, 2019 - Study met the primary endpoint of Overall Response Rate (ORR). Interim data to be presented in an oral presentation at the 2019 American Association of Cancer Research (AACR) annual meeting on April 1, 2019.

read article

Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data

(Yahoo! Finance) Feb 27, 2019 - Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models.

read article

Trovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC at the American Association for Cancer Research Annual Meeting

(Trovagene) Feb 28, 2019 - Trovagene, Inc. today announced that two abstracts, highlighting data from the Company's lead clinical programs of onvansertib in Acute Myeloid Leukemia (AML) and metastatic Castration-Resistant Prostate Cancer (mCRPC), respectively, have been accepted for presentation at the AACR Annual Meeting.

read corporate press release

First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting

(MarketWatch) Feb 27, 2019 - First in-human clinical presentation of company’s PNK allogeneic cell therapy in patients with acute myeloid leukemia- clinical presentation of company’s PNK allogeneic cell therapy in patients with multiple myeloma.

read article

Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research (AACR) Annual Meeting 2019

(Atara) Feb 27, 2019 - Atara Biotherapeutics, Inc. today announced presentations highlighting next-generation CAR T platform and mesothelin-targeted CAR T clinical safety and efficacy results from Memorial Sloan Kettering Cancer Center (MSK) at the AACR Annual Meeting 2019.

read corporate press release

Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019

(The Street) Feb 27, 2019 - Nektar Therapeutics today announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the AACR Annual Meeting 2019.

read article

A Cancer Drug Tailored To Your Tumor? Experts Trade Barbs Over 'Precision Oncology'

(Science Magazine) Apr 24, 2018 - Last week, two prominent voices in the field faced off in a sometimes-tense debate on what’s often called precision oncology at the annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois. Their dispute threw a splash of cold water on a meeting packed with sessions on genome-based cancer treatments.

read article

Three Solutions to Maximize the Clinical Benefit and Affordability of Targeted Cancer Drugs

(Penn LDI) Apr 18, 2018 - Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer. One of the biggest drivers of this growth is targeted cancer drugs.

read article

Roswell Park Researchers Identify Epigenetic Changes that May Help Explain Racial Disparities in Breast Cancer

(RPCI) Apr 18, 2018 - Roswell Park Comprehensive Cancer Center researchers have identified epigenetic differences in the breast cancer tumors of African-American women and women of European descent, shedding light on one mechanism by which race may influence the way breast cancer develops.

read press release

Blood Test Shows Promise For Spotting Early Cancers

(Science Magazine) Apr 17, 2018 - The elusive dream is that a simple blood test could detect a small tumor growing in your body, giving doctors time to cure you before it’s too late. Today, scientists at GRAIL, a biotechnology company based in Menlo Park, California, that has drawn more than a billion dollars in investment, announced progress toward that goal here at the annual meeting of the American Association for Cancer Research.

read article

GRAIL Announces Data from Prototype Blood Tests for Early Cancer Detection

(MarketWatch) Apr 17, 2018 - GRAIL, Inc. today announced initial results from its Circulating Cell-Free Genome Atlas (CCGA) Study. Data from three prototype genome sequencing assays showed it may be feasible to develop a blood test for early detection of multiple cancer types with greater than 99 percent specificity.

read article
Next Page